Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Bristol-Myers Squibb Co    BMY   US1101221083

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Biocon, Bristol-Myers Squibb Sign Pact for Experimental Oral Insulin Drug

11/15/2012 | 11:26pm US/Eastern
   By Rumman Ahmed 
 

BANGALORE, India--Biocon Ltd. (532523.BY) Friday said it has entered into an agreement with Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) on a licensing deal for its experimental biopharmaceutical drug IN-105, which is an orally administered insulin.

Under the terms of the agreement, the New York-headquartered company will have the right to exercise an option to obtain a global license for IN-105 on the successful completion of mid-stage trials for the experimental drug by Biocon, the Indian company said in a statement.

Biocon, which develops biological treatments that use proteins manufactured in living cells, is India's largest biotechnology company by revenue.

It has been seeking alliances with other drug makers for further development of the experimental drug under a licensing agreement.

If Bristol-Myers Squibb decides to obtain the license for IN-105, the U.S. company will assume full responsibility for the development program, including all development and commercialization activities outside India, the statement said.

In return, Biocon will receive a license fee, potential payments when IN-105 achieves certain regulatory and commercial milestones, as well as royalties on commercial sales of IN-105 outside India, the statement added.

Biocon will retain exclusive rights to IN-105 in India.

Indian drug makers often seek to develop drugs in partnership with foreign companies because they can help finance costly and lengthy research. At the same time, global companies are keen to cooperate with Indian companies because of lower costs, the availability of skilled scientists in the South Asian country, as well as the prospect of adding new products to their portfolios.

Write to Rumman Ahmed at rumman.ahmed@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bristol Myers Squibb Co.
Latest news on BRISTOL-MYERS SQUIBB CO
1d agoBRISTOL-MYERS SQUIBB CO : quaterly earnings release
3d agoDJMARKET SNAPSHOT : More Than 1/3 of Dow Stocks To Report This Week
5d ago Danone decides on Mead Johnson as takeover target - sources
6d ago BRISTOL MYERS SQUIBB : Pharmacyclics and Janssen Join Forces
7d ago BRISTOL MYERS SQUIBB : Trademark Application for "UZANTEV" Filed
7d ago BRISTOL MYERS SQUIBB : An Application for the Trademark "DEMVEP" Has Been Filed ..
7d ago BRISTOL MYERS SQUIBB : An Application for the Trademark "JEQUED" Has Been Filed ..
7d ago BRISTOL MYERS SQUIBB : An Application for the Trademark "OPDIVO" Has Been Filed ..
7d ago BRISTOL MYERS SQUIBB : Research Conducted at Bristol-Myers Squibb Has Updated Ou..
7d ago BRISTOL MYERS SQUIBB : Statement about Asunaprevir in the U.S.
Advertisement
Chart
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF